The Identification of Medicinal Products (IDMP) is a suite of five interrelated standards for the unique identification of medicinal products.
Ta-Jen Chen, Project Management Officer with the U.S. FDA described the IDMP standards, the importance of IDMP, and the status of global harmonisation.
The IDMP standard outlines the required details and information for uniquely identifying/describing a medicinal product—its main substance, strength, dosage etc. The data model meets regulatory requirements to primarily support adverse event reporting and other processes.
Critical for interoperability, the IDMP standard enables the sharing of information about medicinal products and allows manufacturers to effectively communicate with regulators and regulators, in turn, to communicate with their constituents. In short, IDMP provides granular detail for a high-level of accuracy and improved risk management—all leading to greater patient safety.
Review the presentation
IDMP and GS1 standards work collaboratively to ensure unambiguous, unique identification of products, as detailed in the recently released position statement which explains that IDMP data model provides a placeholder for the GS1 Global Trade Item Number (GTIN) for physical trade item packaging identification.
The paper is available here